Literature DB >> 20356642

Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): A comparative analysis of toxicities and clinical outcomes.

Annemarie T Fernandes1, Jason Shen, Jarod Finlay, Nandita Mitra, Tracey Evans, James Stevenson, Corey Langer, Lilie Lin, Stephen Hahn, Eli Glatstein, Ramesh Rengan.   

Abstract

BACKGROUND: Elective nodal irradiation (ENI) and involved field radiotherapy (IFRT) are definitive radiotherapeutic approaches used to treat patients with locally advanced non-small cell lung cancer (NSCLC). ENI delivers prophylactic radiation to clinically uninvolved lymph nodes, while IFRT only targets identifiable gross nodal disease. Because clinically uninvolved nodal stations may harbor microscopic disease, IFRT raises concerns for increased nodal failures. This retrospective cohort analysis evaluates failure rates and treatment-related toxicities in patients treated at a single institution with ENI and IFRT.
METHODS: We assessed all patients with stage III locally advanced or stage IV oligometastatic NSCLC treated with definitive radiotherapy from 2003 to 2008. Each physician consistently treated with either ENI or IFRT, based on their treatment philosophy.
RESULTS: Of the 108 consecutive patients assessed (60 ENI vs. 48 IFRT), 10 patients had stage IV disease and 95 patients received chemotherapy. The median follow-up time for survivors was 18.9 months. On multivariable logistic regression analysis, patients treated with IFRT demonstrated a significantly lower risk of high grade esophagitis (Odds ratio: 0.31, p = 0.036). The differences in 2-year local control (39.2% vs. 59.6%), elective nodal control (84.3% vs. 84.3%), distant control (47.7% vs. 52.7%) and overall survival (40.1% vs. 43.7%) rates were not statistically significant between ENI vs. IFRT.
CONCLUSIONS: Nodal failure rates in clinically uninvolved nodal stations were not increased with IFRT when compared to ENI. IFRT also resulted in significantly decreased esophageal toxicity, suggesting that IFRT may allow for integration of concurrent systemic chemotherapy in a greater proportion of patients. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20356642     DOI: 10.1016/j.radonc.2010.02.007

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  22 in total

Review 1.  Individualized image-based lymph node irradiation for prostate cancer.

Authors:  Hanneke J M Meijer; Oscar A Debats; Emile N J Th van Lin; Marco van Vulpen; J Alfred Witjes; Wim J G Oyen; Jelle O Barentsz; Johannes H A M Kaanders
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

Review 2.  Are three doses of stereotactic ablative radiotherapy (SABR) more effective than 30 doses of conventional radiotherapy?

Authors:  Anna O Simeonova; Katharina Fleckenstein; Hansjörg Wertz; Anian Frauenfeld; Judit Boda-Heggemann; Frank Lohr; Frederik Wenz
Journal:  Transl Lung Cancer Res       Date:  2012-03

3.  Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer.

Authors:  Michael Mix; Nithya Ramnath; Jorge Gomez; Charles de Groot; Saju Rajan; Shiva Dibaj; Wei Tan; Youcef Rustum; Michael B Jameson; Anurag K Singh
Journal:  World J Clin Oncol       Date:  2015-10-10

Review 4.  Multidisciplinary approach in stage III non-small-cell lung cancer: standard of care and open questions.

Authors:  Carmen Vallejo Ocańa; Pilar Garrido López; Ignacio Muguruza Trueba
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

Review 5.  PET-CT for radiotherapy treatment planning and response monitoring in solid tumors.

Authors:  Johan Bussink; Johannes H A M Kaanders; Winette T A van der Graaf; Wim J G Oyen
Journal:  Nat Rev Clin Oncol       Date:  2011-01-25       Impact factor: 66.675

6.  Pattern of lymph node metastases and its implication in radiotherapeutic clinical target volume in patients with non-small-cell lung cancer: a study of 2062 cases.

Authors:  Y-X Wang; B-Sh Li; W Huang; Y Yi; J Zhang; Zh-T Wang; H-F Sun; H-Sh Li; Y-M Wei
Journal:  Br J Radiol       Date:  2015-06-30       Impact factor: 3.039

7.  Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study.

Authors:  Aparna H Kesarwala; Christine J Ko; Holly Ning; Eric Xanthopoulos; Karl E Haglund; William P O'Meara; Charles B Simone; Ramesh Rengan
Journal:  Clin Lung Cancer       Date:  2014-12-09       Impact factor: 4.785

8.  Comparison of Toxicity Between Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy for Locally Advanced Non-small-cell Lung Cancer.

Authors:  Diane C Ling; Clayton B Hess; Allen M Chen; Megan E Daly
Journal:  Clin Lung Cancer       Date:  2015-08-03       Impact factor: 4.785

9.  Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer.

Authors:  Steven E Schild; Wen Fan; Thomas E Stinchcombe; Everett E Vokes; Suresh S Ramalingam; Jeffrey D Bradley; Karen Kelly; Herbert H Pang; Xiaofei Wang
Journal:  J Thorac Oncol       Date:  2018-10-04       Impact factor: 15.609

Review 10.  Assessing the interactions between radiotherapy and antitumour immunity.

Authors:  Clemens Grassberger; Susannah G Ellsworth; Moses Q Wilks; Florence K Keane; Jay S Loeffler
Journal:  Nat Rev Clin Oncol       Date:  2019-06-26       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.